Top Markets
#1 Siren Siren +39.19%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.65%
#3 Ocean Protocol Ocean Protocol +17.20%
#4 KUB Coin KUB Coin +14.89%
#5 Audiera Audiera +11.92%
#6 Perle Perle +10.80%
#7 Arowana Arowana +9.87%
#8 Geodnet Geodnet +9.30%
#9 Nockchain Nockchain +9.22%
#10 Wiki Cat Wiki Cat +8.40%
Coin of the day
Siren Siren
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Antibe Therapeutics Inc. Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

ATE
Clasificación en acciones #32097
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Precio por acción
$0.21483059
Última sincronización: 2024-05-07
Capitalización bursátil
$11.13M
Cambio (1 día)
0.34%
Cambio (1 año)
0.00%
País
CA
Comercio Antibe Therapeutics Inc. (ATE)

Categoría

Healthcare
Ganancias de Antibe Therapeutics Inc. (ATE)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Antibe Therapeutics Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Antibe Therapeutics Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
$7.51B -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
$5.15B -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
$5.56B -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
$3.86B -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
$1.42B -
US